Group 1 - Guangshentang's stock price increased by 7.52% to 131.76 CNY per share, with a trading volume of 1.293 billion CNY and a turnover rate of 7.58%, resulting in a total market capitalization of 20.985 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] - The company was established on June 28, 2001, and went public on April 22, 2015 [1] Group 2 - Among Guangshentang's top ten circulating shareholders, a fund under China Europe Fund reduced its holdings by 1.1365 million shares, now holding 708,100 shares, which represents 0.52% of the circulating shares [2] - The China Europe Medical Health Mixed A Fund (003095) has a total scale of 13.843 billion CNY and has achieved a year-to-date return of 1.4% [2] - The fund's one-year return is 16.05%, ranking 5591 out of 8127 in its category [2] Group 3 - The fund manager of China Europe Medical Health Mixed A is Ge Lan, who has a tenure of 11 years and 16 days, with a total asset scale of 35.389 billion CNY and a best fund return of 96.69% during her tenure [3] - Zhao Lei, the other fund manager, has a tenure of 222 days, managing assets of 26.943 billion CNY, with a best fund return of 2.29% during his tenure [3]

中欧医疗健康混合A（003095）基金经理为葛兰、赵磊。 1月28日，广生堂涨5.66%，截至发稿，报97.32元/股，成交4.67亿元，换手率3.64%，总市值155.00亿 元。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 从广生堂十大流通股东角度 数据显示，中欧基金旗下1只基金位居广生堂十大流通股东。中欧医疗健康混合A（003095）三季度减 持113.65万股，持有股数70.81万股，占流通股的比例为0.52%。根据测算，今日浮盈赚取约368.95万 元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模138.43亿。今年以来收益2.06%，同 类排名6843/8864；近一年收益19.88%，同类排名5406/8126；成立以来收益99.16%。 截至发稿，葛兰累计任职时间11年3天，现任基金资产总规模35 ...

资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 截至9月30日，广生堂股东户数4.58万，较上期增加125.95%；人均流通股2985股，较上期减少55.74%。 2025年1月-9月，广生堂实现营业收入3.16亿元，同比减少3.21%；归母净利润-1.12亿元，同比减少 57.96%。 分红方面，广生堂A股上市后累计派现8464.85万元。近三年，累计派现0.00元。 1月15日，广生堂跌4.07%，成交额7.42亿元。两融数据显示，当日广生堂获融资买入额5014.59万元， 融资偿还5334.09万元，融资净买入-319.50万元。截至1月15日，广生堂融资融券余额合计1.50亿元。 融资方面，广生堂当日融资买入5014.59万元。当前融资余额1.50亿元，占流通市值的1.08%。 融券方面，广生堂1月15日融券偿还0.00股，融券卖出0.0 ...

1月15日，广生堂跌5%，截至发稿，报86.62元/股，成交6.17亿元，换手率5.11%，总市值137.96亿元。 赵磊累计任职时间196天，现任基金资产总规模329.54亿元，任职期间最佳基金回报10.2%， 任职期间 最差基金回报3.72%。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 从广生堂十大流通股东角度 数据显示，中欧基金旗下1只基金位居广生堂十大流通股东。中欧医疗健康混合A（003095）三季度减 持113.65万股，持有股数70.81万股，占流通股的比例为0.52%。根据测算，今日浮亏损失约322.92万 元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模169.77亿。今年以来收益9.05%，同 类排名1139/8840；近一年收益27.73%，同类排名4489/8094；成立以来收益112.8 ...

Core Viewpoint - Guangshentang's stock price has shown volatility, with a recent decline of 2.06% and a total market capitalization of 14.22 billion yuan, reflecting ongoing challenges in revenue and profit margins [1][2]. Financial Performance - For the period from January to September 2025, Guangshentang reported a revenue of 316 million yuan, a year-on-year decrease of 3.21% [2]. - The company's net profit attributable to shareholders was -112 million yuan, representing a significant year-on-year decline of 57.96% [2]. Stock Market Activity - As of January 15, Guangshentang's stock was trading at 89.30 yuan per share, with a trading volume of 141 million yuan and a turnover rate of 1.14% [1]. - The stock has experienced a slight increase of 0.17% year-to-date, but has seen a decline of 1.94% over the last five trading days and a more substantial drop of 24.60% over the past 60 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 45,800, a rise of 125.95% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 55.74% to 2,985 shares [2]. Dividend History - Since its A-share listing, Guangshentang has distributed a total of 84.65 million yuan in dividends, with no dividends paid in the last three years [3]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 1.7463 million shares as a new investor [3]. - The fund "China Europe Medical Health Mixed A" ranked as the ninth-largest circulating shareholder, holding 708,100 shares, a decrease of 1.1365 million shares from the previous period [3].

Core Viewpoint - Guangshentang's stock price has shown fluctuations, with a recent increase of 2.04% on January 9, 2025, while facing significant challenges in revenue and profit margins [1][2]. Group 1: Stock Performance - As of January 9, 2025, Guangshentang's stock price reached 92.93 CNY per share, with a trading volume of 4.25 billion CNY and a turnover rate of 3.44%, resulting in a total market capitalization of 14.801 billion CNY [1]. - Year-to-date, Guangshentang's stock has increased by 4.24%, with a 4.24% rise over the last five trading days, a 1.40% increase over the last 20 days, and a decline of 22.56% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Guangshentang reported a revenue of 316 million CNY, reflecting a year-on-year decrease of 3.21%, while the net profit attributable to shareholders was -112 million CNY, a significant decline of 57.96% year-on-year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 84.6485 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, Guangshentang had 45,800 shareholders, an increase of 125.95% from the previous period, with an average of 2,985 circulating shares per shareholder, down by 55.74% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest with 1.7463 million shares, while the China Europe Medical Health Mixed A fund has reduced its holdings by 1.1365 million shares, now holding 708,100 shares [3].

Group 1 - The core viewpoint of the news is that Guangshentang's stock has shown significant volatility, with a year-to-date increase of 173.77%, but recent trends indicate a decline over the past 20 and 60 days [1] - As of December 24, Guangshentang's stock price was 89.44 yuan per share, with a market capitalization of 14.245 billion yuan [1] - The company has seen a net inflow of main funds amounting to 471,200 yuan, with significant buying activity from large orders [1] Group 2 - As of September 30, the number of shareholders for Guangshentang increased by 125.95% to 45,800, while the average number of circulating shares per person decreased by 55.74% to 2,985 shares [2] - For the period from January to September 2025, Guangshentang reported an operating income of 316 million yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of -112 million yuan, down 57.96% year-on-year [2] - Since its A-share listing, Guangshentang has distributed a total of 84.6485 million yuan in dividends, with no dividends paid in the last three years [3]

12月19日，广生堂涨5.02%，截至发稿，报90.63元/股，成交2.48亿元，换手率2.05%，总市值144.34亿 元。 责任编辑：小浪快报 同泰大健康主题混合A（011002）成立日期2021年4月8日，最新规模1375.12万。今年以来收益11.87%， 同类排名5281/8098；近一年收益6.25%，同类排名6196/8067；成立以来亏损54.1%。 同泰大健康主题混合A（011002）基金经理为马毅、麦健沛。 截至发稿，马毅累计任职时间11年278天，现任基金资产总规模27.18亿元，任职期间最佳基金回报 42.13%， 任职期间最差基金回报-5.55%。 麦健沛累计任职时间222天，现任基金资产总规模2.31亿元，任职期间最佳基金回报20.94%， 任职期间 最差基金回报-5.55%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号 ...

Core Viewpoint - Guangshentang experienced a decline of 5.01% on December 2, with a stock price of 94.54 CNY per share and a total market capitalization of 15.057 billion CNY [1] Company Overview - Fujian Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015 [1] - The company's main business involves the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications and 1.46% from other supplementary products [1] Fund Holdings - Jin Xin Fund has one fund heavily invested in Guangshentang, specifically the Jin Xin Value Selection Mixed A (005117), which held 11,000 shares, accounting for 3.65% of the fund's net value, ranking as the eighth largest holding [2] - The fund has experienced a floating loss of approximately 54,900 CNY today [2] Fund Performance - Jin Xin Value Selection Mixed A (005117) was established on September 1, 2017, with a current scale of 13.4048 million CNY [2] - Year-to-date return is 52.18%, ranking 741 out of 8122 in its category; the one-year return is 47.38%, ranking 869 out of 8056; and since inception, the return is 70.76% [2] Fund Manager Information - The fund managers are Liu Shang and Tan Zhiming, with Liu having a tenure of 102 days and a total fund size of 109 million CNY, while Tan has a tenure of 237 days with a total fund size of 141 million CNY [3] - Liu's best and worst fund returns during his tenure are -7.2% and -14.03%, respectively, while Tan's best and worst returns are 33.16% and -2.98% [3]

Group 1 - The core point of the news is that Guangshentang's stock price dropped by 5.09% to 102.88 CNY per share, with a trading volume of 722 million CNY and a turnover rate of 5.01%, resulting in a total market capitalization of 16.385 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015. The company specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B [1] - The main business revenue composition of Guangshentang is 98.54% from liver and gallbladder disease drugs and 1.46% from other supplementary products [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund holds a position. The China Europe Medical Health Mixed A Fund (003095) reduced its holdings by 1.1365 million shares in the third quarter, now holding 708,100 shares, which accounts for 0.52% of the circulating shares [2] - The estimated floating loss for the China Europe Medical Health Mixed A Fund today is approximately 3.909 million CNY. The fund was established on September 29, 2016, with a latest scale of 16.977 billion CNY, and has achieved a year-to-date return of 21.69% [2] - The fund's one-year return is 13.44%, ranking 5002 out of 8053 in its category, while since its inception, it has achieved a return of 110.03% [2]